Extensive dissection of retroperitoneal lymph node (LN) collectors during D2 lymph node dissection inevitably leads to the crossing of a large number of lymphatic ducts with an increased risk of lymph leakage into the abdominal cavity and a potential risk of intraperitoneal dissemination of free malignant cells. The increased risk of intraperitoneal recurrence of gastric cancer (GC) after advanced lymph node dissection remains unclear. The aim of our study was to investigate an advanced lymph node dissection during surgical treatment of gastric cancer as a separate potential predictor of intraperitoneal relapse.

 The level of intraperitoneal recurrence and peritoneal recurrence free survival (PRFS) in 226 patients with localized and locally advanced GC after radical surgery with different levels of lymph node dissection were analyzed.

 The average number of removed LN was 22.94 ± 11.46 (from 4 to 67). There was a statistically significant difference (χ2 = 110.75; p = 0.0001) in the number of removed LN during lymph node dissection of different levels (D0, D1, D1 +, D2). In the long term the overall level of GC progression did not differ in patients with D0,1 (n = 110) and D1+,2 (n = 116) lymph node dissections - 40% and 38,79%, respectively (χ2 = 0.03; p = 0,85). The level of loco-regional recurrences (in regional groups of LN) in subgroup D0,1 was twice as high as in subgroup D1+,2 - 14.55% and 7.76%, respectively (χ2 = 2.67; p = 0.102). Tendency (p = 0.32) to increase the overall 5-year survival by 8.3% with D1+,2 was recorded. No significant increase in the level of intraperitoneal recurrences after advanced lymph node dissection was detected: in subgroup D0,1 they were recorded in 23 (20.9%) patients, in subgroup D1+,2 - in 22 (19%) (χ2 = 0.13; p = 0.72). The level of 2-year PRFS was the same in both subgroups: 77.2% with D0,1 and 82.8% with D1+,2 (p = 0.6, HR 0.36, 95% CI 0.5-3.68). No effect of  D1+,2 on the level of PRFS was found in the subgroup of patients with diffuse/mixed GC and pN+ (p = 0.62), and in the subgroup of patients with high (> 0.2) index of regional LN lesion (p = 0.8). At the same time, a significant increase of 5-year overall survival of patients with diffuse/mixed GC type with D1+,2 lymph node dissection was found (p = 0.048), and loss of efficacy of this level of lymph node dissection in cases of gastric serous membrane area lesion > 5 cm2. 

Carrying out D1+,2 lymph node dissection during surgical treatment of GC does not increase the risk of intraperitoneal recurrence in the long term. The effect of D1+,2 lymph node dissection on overall survival is offset by intraperitoneal relapse in patients with diffuse/mixed type of GC and serous membrane lesion area > 5 cm².

Purpose: Inferior vena cava (IVC) involvement by renal cell carcinoma (RCC) is associated with a higher disease stage and is considered a risk factor for poor prognosis. This study aimed to investigate the role of the apparent diffusion coefficient (ADC) of MRI 3D texture analysis in the differentiation of solid and friable tumour thrombus in patients with RCC.

Materials and methods: The study involved 27 patients with RCC with tumour thrombus in the renal vein or IVC, surgically treated with nephrectomy and thrombectomy and in whom preoperatively abdominal MRI including the DWI sequence was conducted. For 3D texture analysis, the ADC map was used, and the first-order radiomic features were calculated from the whole volume of the thrombus. All tumour thrombi were histologically clas sified as solid or friable.

Results: The solid and friable thrombus was detected in 51.9 % and 48.1 % of patients, respectively. No differences in mean values of range, 90th percentile, interquartile range, kurtosis, uniformity and variance were found between groups. Equal sensitivity and specificity (93 % and 69 %, respectively) of ADC mean, median and entropy in differentiation between solid and friable tumour thrombus, with the highest AUC for entropy (0.808), were observed. Applying the skewness threshold value of 0.09 allowed us to achieve a sensitivity of 86 % and a specificity of 92 %.

Conclusions: In patients with RCC and tumour thrombus in the renal vein or IVC, the 3D texture analysis based on ADC-map allows for precise differentiation of a solid from a friable thrombus.

Objective. The aim of our study was to research the engagement and personal contribution to volunteering of pharmaceutical professionals and students in conditions of Russian-Ukrainian war.
Methods. An anonymous online questionnaire-based survey was conducted among Ukrainian pharmaceutical professionals and students (n = 517; approximate response rate - 40%). e analyzed period was February-April 2023.
Statistical analysis was performed using a spreadsheet Microso Excel.
Results. The results of the questionnaire survey have shown that almost two thirds of respondents (63.45%) were engaged in volunteer activities. e most relevant sources of information about volunteering were pages, channels and
groups of volunteer organizations in social networks (22.21% of responses), information from friends, colleagues,
relatives, etc., related to volunteering (21.86%), various announcements in social networks (20.83%). Leaders among social networks were Telegram (28.32%), Instagram (28.05%) and Facebook (23.58%). The main motives for volunteering were the desire to help the army (43.57%) and internally displaced persons (25.73%), and the main forms of participation in volunteer activities were the collection of funds, clothes, household items, food and medicines (24.31%), transfer of funds for the needs of the army (17.36%) and for volunteer activities (17.26%).
Conclusion. The role of volunteering in the conditions of the Russian-Ukrainian war among pharmacists and pharmaceutical students was studied and understood.

Healthcare plays a crucial role in public and national safety as a significant part of state activity and a component of national safety, whose mission is to organize and ensure affordable medical care for the population. The four stages of the genesis of healthcare safety development with the corresponding safety models of formation were defined: technical, human factor or security management, systemic security management, and cognitive complexity. It was established that at all stages, little attention is paid to the issues of the formation of the pharmaceutical sector’s safety.
Taking into account the development of safety models that arise during the four stages of the genesis of safety science, we have proposed a model of the evolution of pharmaceutical safety formation.
At the same time, future research is proposed to focus on new holistic concepts of safety, such as “Safety II”, evaluation and validation methods, especially in the pharmaceutical sector, where the development of this topic remained in the second stage of the evolution of science, the search for pharmaceutical errors related to drugs.

My interest in specific nanomaterials and nanobiotechnologies for biology and medicine started in 2005, when a couple of my colleagues who are organic and physical chemists sent me a proposal to investigate the biological activities of their products in order to evaluate the potential biomedical applications of the synthe-sized products. The role of my department at the Institute of Cell Biology, NAS of Ukraine, was to study the possibility of using new products, organic polymers and C60-fullerene nanoparticles, as platforms for drug and gene delivery. The need for such platforms exists because of the inaction of many medicines and their adverse effects in the treated organism. In addition, the physicochemical properties of many drugs, for example, with their poor water solubility, do not allow for a convenient application of these drugs. As a result of the realization of joint research projects with my colleagues working in Eastern and Central European countries, several nanoplatforms were developed for drug and gene delivery. Thus, there was a need
for the analysis and summarization of our experience in the molecular design, chemical synthesis, and biomedical application of novel nanomaterials in order to pass that experience to other scientists who work in this rapidly developing field of materials science. Most co-authors of this book participated in the TechConnect World Innovation Conference in Washington, DC (USA), in 2017. Their oral and poster presentations were visited by Merry Stuber, Senior Editor with Springer Nature Publishers. She asked Dr. Sandor Vari, Director of International Research and Innovation in Medicine Program (Cedars-Sinai Medical Center, Los Angeles, CA, USA) and RECOOP Association (https://www.cedars-sinai.org/research/administration/recoop.html), who managed our participation at the TechConnect World Innovation Conference, if he would prepare a book devoted to our results in the development of novel nanomaterials and nanobiotechnologies for biomedical use. This initiative was interrupted by COVID-19-related problems, but finally, we can present our
book to readers. The logistics of composing the presented materials is based on offering to read-ers a unique manual for their strategy for developing their own nanomaterials for biomedical applications, starting from their molecular design and synthesis, and moving to necessary steps of their physical-chemical and toxicological characteris-tics (biodegradability, biocompatibility, controlled delivery and clearance in the organism, as well as potential bio-risks for the environment). Both the organic (novel surface-active comb-like PEG-containing polymers) and mineral (novel water-soluble C60-fullerene-based nanoplatforms and magnetic iron oxide-based nano- and micro-particles for theranostics) materials used in biomedical applica-tions are described by the leading specialists in the corresponding fields. The nano-toxicology-related aspects of these and other biomedical materials are described
both in general, including genotoxicity and environmental toxicity, and specifically, hepato-, cardio-, nephro-, and immune-toxicities. Environmental aspects of the application of various nanomaterials have been characterized for freshwater and marine organisms, as well as for the multipollutant strategy of assessment of the environmental quality and health risks caused by air nano-pollutants. Bioimaging of nanomaterials is a central element for monitoring their biological action, and this aspect is described in the book as characterization of novel polymeric nanocarriers for gene delivery, which is a crucial step in gene therapy that is considered to be the future of medicine. The co-authors of all chapters of this book are thankful to the people who initi-
ated its writing, as well as to numerous members of the research teams who assisted in the experiments aimed at the development of novel nanomaterials and nanobio-technologies for biomedical applications.